Compare Pfizer Inc (PFE) vs Planet Labs (PL) Price & Performance

Pfizer (PFE) trades at $27.78, down 2.36% today, with a consensus price target of $28.33 suggesting modest upside. The stock shows mixed technical signals with bullish moving averages but neutral oscillators. Recent earnings have consistently beaten expectations, though revenue declined from pandemic peaks. The company maintains strong cash flow generation and a solid dividend yield of approximately 3.1%.

Pfizer presents a value opportunity with reasonable valuation metrics and dividend stability, but faces headwinds from post-COVID revenue normalization and patent expirations. The company's pipeline progress in obesity and oncology could drive future growth, though execution risks remain. Analyst sentiment leans cautious with 59% hold ratings.

Planet Labs (PL) trades at $17.81, down 1.71% today, with a neutral technical signal. The company reported a strong Q2 2027 earnings beat, with revenue up 58% year-over-year to $116 million, and raised its full-year guidance. However, it remains unprofitable, with a net income margin of -95.13% in 2025. Analyst sentiment is positive, with a consensus price target of $38.33 and 56.52% of analysts rating it a Buy.

The outlook is mixed; strong revenue growth and a large satellite-services pipeline offer upside, but persistent losses and high valuation multiples pose significant risks. Investors should weigh the growth potential against the company's current lack of profitability and the capital-intensive nature of the space industry.